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Basal cell carcinomas (BCCs) are locally destructive malignancies of the skin. They are the most common type of cancer in the
western world. The lifetime incidence may be up to 39%. UV exposure is the most common risk factor. The majority of these
tumours occur on the head and neck. Despite BCCs being relatively indolent the high incidence means that their treatment
now contributes a signiﬁcant and increasing workload for the health service. A good understanding of the options available is
important. Management decisions may be inﬂuenced by various factors including the patient’s age and comorbidities and the
lesion subtype and location. Due to the importance of a good cosmetic and curative outcome for facial BCCs treatment decisions
may diﬀer signiﬁcantly to those that would be made for BCCs arising elsewhere. There is little good randomized controlled data
availablecomparingtreatment modalities.Althoughtraditionallystandardexcisionhas been the treatment ofchoice various other
options are available including: Mohs micrographic surgery, curettage and cautery, cryosurgery, radiotherapy, topical imiquimod,
photodynamictherapy andtopical5-ﬂuorouracil.Wediscussandreview theliterature andevidence baseforthetreatment options
that are currently available for facial BCCs.
1.Introduction
Basal cell carcinomas (BCCs) are locally destructive malig-
nancies of the skin. They are the most common type of
cancer in Europe, Australia [1] and the U.S.A [2]. A Cana-
dian study found the lifetime incidence in the Caucasian
population to be between 15%–28% in women and 17%–
39% in men [3]. In the U.K. the true incidence is not known
due to inconsistencies in cancer registration [4]. However,
estimates suggest that 53,000 new cases are diagnosed in the
UK each year [5]. Despite BCCs being relatively indolent the
high incidence means that the treatment of these tumours
contributes a signiﬁcant and ever growing workload for the
NHS.
The most signiﬁcant aetiological factors appear to be
exposure to ultraviolet radiation and genetic predisposition
[6]. BCCs tend to occur in areas of chronic sun exposure and
thereforealargeproportion,around74%,occursonthehead
and neck [3]. Although BCCs are usually slow growing and
rarely metastasize [7], local destruction, and disﬁgurement
may occur if left untreated or if incompletely removed [8].
Management is dependent upon a variety of factors,
including the location of the lesion, the patient’s age, comor-
bidities and the type of tumour involved. The location of
the lesion is important, as tumours that arise in cosmetically
or functionally important areas are best managed with
treatments that minimise the amount of tissue removed
whilst ensuring a high chance of complete cure. In the
elderly population, the slow growing nature of BCCs means
that less invasive treatments may be favoured despite the
fact that some of these methods have higher recurrence
rates. Cystic and nodular BCCs (nBCC) have relatively well
deﬁned borders, while morphoeic, micronodular, trabecular,
inﬁltrative and basosquamous BCCs are often less well
deﬁned and are also more aggressive [9]. Superﬁcial BCCs
(sBCC) may be amenable to topical treatments as a result of
their minimal depth of invasion.
Over recent years, various treatments beside traditional
e x c i s i o nh a v eb e e nt r i e di na ne ﬀort to provide better results,
in terms of reduction of recurrence, better patient accept-
ability, and improved cosmesis. Although many treatments
are now used for BCCs, there is little research that accurately
compares these diﬀerent treatment modalities against each
other for diﬀerent types of tumours in diﬀerent locations. As
a result of the importance of a good cosmetic outcome when
tumours arise on the face treatment decisions may diﬀer2 Journal of Skin Cancer
signiﬁcantly to those that would be made for BCCs arising
elsewhere. We discuss and review the literature and evidence
base forthe treatment optionsthat are currently available for
facial BCCs.
2.SurgicalManagement
2.1. Standard Excision of Primary BCC with Predetermined
Margins. Standard surgical excision is a highly eﬀective
treatment for primary BCC and historically has been the
mostly common treatment option. BCCs are generally
removed with a predetermined excision margin of 3-4mm
of normal skin. Especially on the face, grafts and ﬂaps may
be necessary to close the wound, rather than direct closure.
Astudyof2016BCCsbyBreuningerandDietz[10],using
horizontal sections to accurately detect BCC at any part of
the surgical margin, found that excision of small (<10mm
diameter) lesions with a 2-mm peripheral surgical margin
cleared 70%, margins of 3-mm cleared 84% and margins
of 5-mm cleared 95% of all tumours. Morphoeic and large
BCCs required wider surgical margins in order to maximize
t h ec h a n c eo fc o m p l e t ee x c i s i o n .F o rp r i m a r ym o r p h o e i c
lesions, the rate of complete excision was 66% for a 3-mm
margin, 82% for 5-mm and >95% for 13–15mm.
Although little data exists on the correct deep surgical
margin, excision through to the subcutaneous fat is generally
advisable. Overall the 5-year recurrence rate after a simple
excisionofaBCCisreportedasbeingbetween4.1%[11]an d
10.1%[12].Ifthe excision hasbeen reported ashistologically
c om plet ether ecurr enc erat eisr eport edt obe<2%[13].This
isduetosampling errorsthat occurashistological specimens
are examined in a vertical plane.
B a s a lc e l lc a r c i n o m ao nt h ef a c em a yh a v eah i gh e rd e gr e e
of subclincal spread than tumours arising elsewhere.Batra
and Kelley [14] retrospectively analysed 1131 cases of Mohs’
micrographic surgery on the face and found there to be
higher rates of extensive subclinical spread on the nose,
ear, eyelid, temple, and neck than the cheek. The nasal ala,
nasal bridge, nasal tip, ear helix, and lower eyelid were all
found to be locations of particularly high extensive spread.
In addition, morpheaform BCCs were 2.3 times (P<. 001),
recurrent BCCs were 3.2 times (P<. 001), and recurrent
SCCs were 4.2 times (P = .01) more likely than nodular
BCCs to exhibit extensive subclinical spread.
Generally the cosmetic outcome for standard surgical
excision is felt to be good [15]. However, having to remove
large lesions with adequate excision margins can be disﬁg-
uring as a result of loss of tissue, grafting, and subsequent
scarring. Special attentionmust be paid to the locationof the
BCC on the face as there are many areas of functional and
cosmetic importance for example the periocular, perioral,
and perinasal areas.
Various studies of incompletely excised BCCs suggest
that not all recur and in a series of 74 patients Griﬃths
reports residual tumour in just 54% of re-excised tissue [16].
Studies with a 5 year followup have reported recurrence
rates ranging from 21%–41%for patientsfollowing previous
incomplete excisions [17, 18]. However, the study by Wilson
et al. [17] of 140 patients, that reports a recurrence rate of
21% also reports that 31% of the cohort died of other causes
during the (minimum 5-year) followup period and therefore
the incidence may have been higher.
When incomplete excision occurs on the face there
is good evidence to support the need for re-excision.
Boulinguez et al. [19] report a 24% chance of incompletely
excised BCCs becoming more aggressive when they recur,
with thelikelihoodbeinghigherforperinasal, periocularand
periauricular lesions. Although treatment should therefore
be with early re-excision, there is a role for radiotherapy
in special circumstances [20]. Recurrent tumours, especially
on the face, are at high risk of further recurrence following
surgical excision and require wider surgical margins.
Generally standard surgical excision is considered a good
treatment option for all BCCs arising on the face with
5-year recurrence rates of anything up to 10% providing
adequate margins are taken.We would therefore recommend
at least a 3-mm margin for standard surgical excision. While
it would seem sensible to take larger margins at the sites
wheresubclinicalspreadisknowntobemoreextensive,these
sites are all of great cosmetic and functional importance
and therefore striking the correct balance is necessary while
considering the option of Mohs’ micrographic surgery as an
alternative.
2.2. MohsMicrographic Surgery. Mohs micrographic surgery
(MMS) was ﬁrst reported by an American physician and
general surgeon, Dr. Mohs, in 1941 [21]. Excised tissue is
frozen and sectioned horizontally. The entire margin can
then be intraoperatively histologically examined. Further
excision can then be performed if necessary from the
speciﬁcally involvedmargin. MMSallowsgreaterhistological
accuracy and increased tissue conservation.
Studies and reviews have found 5-year cure rates of
between93.5%[22]and100%[23]forprimary tumoursand
90% [22] to 96% [24] for recurrent disease.
A prospective randomised Dutch trial [11, 25]c o m p a r -
ing MMS with standard surgical excision found recurrence
rates to be comparatively lower after MMS for the treatment
of both primary (pBCC) and recurrent BCCs (rBCC). For
pBCCs rates were 2% and 3%, respectively, at 30 months
and 2.5%and 4.1%, respectively, at 5 years. These diﬀerences
were not statistically signiﬁcant. In addition there was
no signiﬁcant diﬀerence in patient perception of cosmetic
appearance following the procedure. For rBCCs, the rates
were 0% and 3%, respectively, at 18 months and 2.4% and
12.1%, respectively, at 5 years. These diﬀerences were only
statistically signiﬁcant (P = .015) at 5 years. In addition,
in the standard surgical group 30% of rBCCs were initially
incompletely excised and required further surgery. This
suggests that MMS should be the treatment of choice for
facial rBCC on the basis of fewer recurrences. However, it
is worth noting that in this study some patients who were
randomised to standard surgical excision were moved to
the MMS treatment group. Recurrent lesions retreated with
t h es a m em o d a l i t yh a v eag r e a t e rr i s ko fr e c u r r e n c ea n di n
such cases MMS will oﬀer the best chance of complete cure
[26].Journal of Skin Cancer 3
Even primary lesions need to be appropriately stratiﬁed
to determine the optimal course of treatment [12, 27].
Histological subtype, location, size of the lesion, age and
patient comorbidities are all important factors to consider.
Guidelines suggest the following as being speciﬁc indica-
tions: Tumour site (especially central face, around the eyes,
nose, lips, and ears), tumour size (any size, but especially
>2cm), histological subtype (especially morphoeic, inﬁl-
trative, micronodular, and basosquamous subtypes), poor
clinical deﬁnition of tumour margins, recurrent lesions, and
perineural or perivascular involvement [28].
MMS is more labour intensive and the cost of each
procedure is signiﬁcantly higher than for standard excision.
However,inview ofthereducedrecurrencerate,MMSiscost
eﬀective treatment for appropriately selected cases. A recent
study comparing Mohs’ surgery to standard excision for
facial and auricular nonmelanoma skin cancer found MMS
to be more cost eﬀectivethan standard surgical excision [29].
Mohs surgery provides the best chance of cure for
all BCCs arising on the face with 5-year recurrence rates
of anything up to 6.5%. However, due to time and cost
limitations, it should be reserved for the treatment of high-
risk primary or recurrent BCCs on the face.
2.3. Curettage with and without Cautery. Curettage is widely
used in management of BCC. The tumour is scraped oﬀ
with a curette and then the base and wound margin is often
treated with electrocautery to control bleeding and destroy
any residual tumour. This may be repeated. As excision
margins are being destroyed it is advisable to conﬁrm the
diagnosis and determine the histological subtype with a
preoperative biopsy,especially for facial lesions, unless a very
conﬁdent clinical diagnosis can been made.
For standard curettage and electrocautery recurrence
rates have been reported to be between 7.7% [12] and 19%
[30] at 5 years. Recurrence rates have beenfound to be much
higher for facial lesions and recurrent disease [30, 31]. A
prospective study of 69 re-excised BCC wounds immediately
after curettage and electrocautery found residual tumour in
47% of head and neck wounds and 8.3% of trunk and limb
wounds[32].Curettageisveryoperatordependant;however,
aretrospectivestudyofcurettagealonereporteda5-yearcure
rate of 96% for nonaggressive BCC, and tumours involving
more than 50% of the deep edge of the specimen were found
to have an increased risk of recurrence [33].
A randomised controlled trial comparing a double freeze
thaw cycle of cryosurgery after curettage with standard
excision for nonaggressive BCC of the head and neck
reports recurrence rates of 17.6% and 8.2%, respectively
[34]. However, there are other studies that report much
lower recurrence rates than this. Lindemalm-Lundstam and
Dalenb¨ ack report a 1.5% recurrence rate following curettage
and cryosurgery for head and neck BCCs after a median
followup of 34-months [35].
Given the disproportionate amount of residual tumour
on head and neck wounds and higher recurrence rates
curettage and electrocautery is not considered ﬁrst line
treatment for BCCs on the face.
2.4. Cryosurgery. Cryosurgery involves the destruction of
tissue using liquid nitrogen. Again, it is advisable to biopsy
ﬁrst to conﬁrm the diagnosis and determine the histological
subtype, especially for facial lesions. It is very operator
dependant, and there are huge variations in practice. Data
is therefore very inconsistent. Cryosurgery tends to be most
useful in the treatment of low risk BCCs although good
results have been reported following treatment of high risk
lesions, either as sole treatment or in combination with
curettage.
Recurrence rates are very variable, but when the lesion
is carefully selected and in expert hands recurrence rates
may be as low as 1% [36]. However, a nonrandomised study
comparing cryosurgery (60 seconds freeze, 90 second thaw 2
× cycles) to radiotherapy found the 2-year recurrence rates
to be 39% and 4%, respectively [37].
Cryosurgery wounds generally heal with minimal tissue
contraction, resulting in good cosmetic results. However, a
study comparing cryosurgery (20 seconds freeze, 60 seconds
thaw 2 × cycles) to standard surgical excision for head and
neck sBCC and small nBCCs found no signiﬁcant diﬀerence
in recurrence rates at 1-year but signiﬁcantly worse cosmetic
outcomes for those who had received cryosurgery [38].
Cryosurgery should not be ﬁrst line in the management
of facial BCCs due to the high risk or recurrence and
potentially poorer cosmetic outcome.
2.5. Laser Ablation. Carbon dioxide laser ablation has been
used in the treatment of BCCs. There are reports of use in
combination with curettage for treatment of low-risk BCCs,
but supportive data is generally lacking.
3.Non SurgicalManagement
3.1. Radiotherapy. Radiotherapy can be used to treat pri-
mary, recurrent or incompletely excised BCCs. It encom-
passes superﬁcial X-ray and electron beam. Brachytherapy
is used for contoured surfaces. The cure rates are over 90%
for most skin lesions [12]. It may be used on tumours that
occur in areas where surgery would either be technically
diﬃcult or would result in unacceptable amounts of tissue
destruction. Radiotherapy therefore plays an important role
in the management of head and neck BCCs. Tumours of
the lower eyelid, inner canthus, lip, nose, and ear may be
amenable to radiotherapy [39]. However, the upper eyelid is
notanappropriatesite forradiotherapyduetokeratinization
of the conjunctiva, lesions on the ear must be treated with
caution due to the risk of damage to the underlying cartilage
and the bridge of the nose is particularly susceptible to
radionecrosis. Radiotherapymaybeagoodoptionforelderly
patients with very large BCCs of the scalp. Radiotherapy is
not appropriate for recurrent BCCs or patients with Gorlin’s
syndrome or with connective tissue disease. It tends not
to be used in younger patients as skin cancers can arise
from radiotherapy ﬁeld scars and long term cosmetic results
are poor. Side eﬀects include radionecrosis, atrophy, and
telangiectasia. Treatment in fractions over several visits may
produce better cosmetic outcomes than a single fraction4 Journal of Skin Cancer
treatment. However, a daily regimen for a period of weeks
may be a signiﬁcant inconvenience to the patient as opposed
to a single surgical treatment.
A randomised trial by Avril et al. [40]c o m p a r i n g
radiotherapy to surgical excision for facial BCC of less than
4cm found 4 year recurrence rates to be 7.3% and 0.7%,
respectively. Cosmetic outcome also signiﬁcantly favoured
surgical excision at 4 years with 87% of patients assessing the
surgical scar as good, compared to 69% after radiotherapy
(P<. 01) [41].
In addition, radiotherapy tends to be more expensive
than any other form of treatment. A recent prospective study
by Lear et al. in Canada [42] looked at the cost of MMS
and radiotherapy for 49 BCCs. The authors found the cost of
radiotherapy to be signiﬁcantly greater and state direct costs
of a “5-year cure” to be $952 (range $644–1,647) for MMS
and $3,758 (range $3,564–4,675)for radiotherapy.
We believe radiotherapy is a good treatment option for
facial BCCs located at diﬃcult sites in patients who are not
able to tolerate surgery.
3.2. Topical 5% Imiquimod Cream (Aldara). Imiquimod is
an immune response modiﬁer. It acts by binding to toll-like
receptor.Thisinducesproinﬂammatory cytokineproduction
and subsequent cytotoxic T cell mediated cell death. It is
licensed for use in the treatment of sBCCs.
Vehicle-controlledstudiesinthetreatmentofsmall sBCC
by Geisse et al. [43] have reported reasonable results. Twelve
weeks following the 6 week treatment course the clearance
rates were 82% (5x/week), 79% (7x/week) and 3% (vehicle
only).Moderatetoseverelocalsitereactionsoccurredin87%
with erosions and ulceration in 36% and 22%, respectively.
However, it is worth noting that facial BCCs were not
included in this study. Schulze et al. [44] found similar
clearance rates following a 6 weeks course of 7x/week topical
imiquimod, with a 80% histological clearance compared
to 6% for vehicle alone. However, long term clearance
rates are lower. A prospective study of 182 patients who
receivedtopicalimiquimod applied 5x/weekfor6 weeks gave
clearance rates of 69% at 5-years [45].
There is some data to suggest that imiquimod may
be used in the treatment of nBCCs. A randomized dose-
response study reported that 6 weeks after treatment with
either a 6- or 12-week course of 7x/week imiquimod histo-
logical clearance rates were 71% and 76%, respectively [46].
A further randomized trial on nBCCs reported complete
clinical clearance in 78% following 3x/week imiquimod.
However, 8 weeks later excision revealed residual BCC in
13% of the patients considered to have shown complete
clinical clearance [47].
In terms of studies speciﬁcally focusing on the treatment
offacialBCCswith5%imiquimodVunandSiller[48]r eport
a retrospective study of 19 lesions involving 12 patients. A
once-daily treatment regimen for up to 9 weeks was used
to treat both superﬁcial and nodular basal cell carcinomas
on the face. The authors report a clearance rate of 89.5% at
an average of 39 months of followup. Another more recent
study from 2010 [49] of ﬁfteen patients with nodular BCCs
on the eyelid, this time treated with 5% imiquimod once
daily,5days/weekfor6weeks, reportsthatalltumorsshowed
histopathological remission within 3 months of starting
treatment, and sustained clinical remission was documented
in each patient after 24–28 months’ followup. The authors
acknowledge that treatment tolerability was diﬃcult in 7
patients with local eﬀects being most problematic, but all
symptoms disappeared when treatment ended and ﬁnal
aesthetic results were rated as excellent. They conclude that
5% imiquimod is a useful alternative to surgery in patients
with periocular BCCswhen othertherapies havefailed orare
not possible.
Studies have also been done investigating the combi-
nation of curettage of nBCC prior to the use of topical
imiquimod. Results have been variable with recurrence rates
ranging from 6% [50] to 10% [51].
Eﬀective treatment with imiquimod is dependent upon
tissue penetration. sBCC may be more amenable to topical
treatments asaresultoftheirminimal depthofinvasion. The
increased depth of nodular tumours results in incomplete
tumourpenetration with the drugand hencelowerclearance
rates.
Imiquimod may be an alternative to surgery for patients
with primary facial superﬁcial BCCs, but long-term clear-
anceisnotasgoodassomeoftheothertreatmentmodalities.
It is not recommended for recurrent disease but is a good
treatment option for elderly frail patients and patients who
are not keen on surgical treatment.
3.3. Photodynamic Therapy (PDT). Photodynamic therapy
(PDT) involves the destruction of sensitised cells by an
irradiating light source. A prodrug, either 5-aminolaevulinic
acid (ALA) or methyl aminolaevulinic (MAL), is applied
to the skin. This is converted intracellularly into protopor-
phyrin IX by the tumour cells. In the presence of intense
red or blue light, a cytotoxic reaction occurs with reactive
oxygen in the cell-membranes of tumour cells containing
protoporphyrin IX and so the tumour cells are destroyed
with sparing of uninvolved skin.
Superﬁcial BCCs have been shown to achieve 87%
clearance [52]. A prospective randomized study comparing
PDT and standard surgical excision for the treatment of
nBCCs found 5 years recurrence rates to be 14% and
4%, respectively; however, cosmesis was better for PDT
with 87% of patients rating the cosmetic outcome as good
compared to 54% for surgery [53]. PDT has also been
compared with cryosurgery in the treatment of both sBCC
and nBCC. Clinical recurrence rates at 12 months of 5%
(PDT) and 13% (cryosurgery) were underestimates, as
histology demonstrated residual BCC in 25% and 15% of
cases, respectively [54].
Vinciullo et al. [55] reported 102 patients with sBCCs
and nBCCs regarded as “diﬃcult to treat” (deﬁned as large
and/or central facial lesions, or patients at increased risk of
surgical complications) who received MAL-PDT treatment.
Histologically conﬁrmed clearance rates at 3 months were
93% (sBCC) and 82% (nBCC). The authors used a time-to-
eventapproach toestimate sustained lesion clearanceratesof
82% (sBCC) and 67% (nBCC) at 24 months.Journal of Skin Cancer 5
Due to the clearance rates being lower than for surgical
treatments, PDT is not generally recommended for manage-
ment of nodular BCCs on the head or neck. While primary
superﬁcial BCCs on the face may be amenable to treatment
is not recommended for recurrent disease.
3.4. Topical 5-Fluorouracil 5% (Efudex). 5-ﬂuorouracil is a
ﬂuorinated pyrimidine that blocks the methylation reaction
of deoxyuridylic acid to thymidylic acid and in doing
so destabilises DNA. It is sometimes used to treat small,
superﬁcial BCCs and should only be used on low risk sites.
It therefore is not recommended in the management of facial
BCCs.
4.Conclusion
We have discussed a number of the diﬀerent treatment
options available for BCCs. However, lesions on the face are
considered high-risk, and therefore, some of the treatment
modalities that would otherwise be considered may not
always be appropriate. It is often necessary to a prior
histological diagnosis, especially if a destructive treatment
is being considered. Mohs micrographic surgery remains
the gold standard, but it is not feasible for it to be oﬀered
to all. Standard surgical excision gives good results in
most cases. Radiotherapy may be considered for patients
where surgery is not an option. Other treatment options
include curettage and electrocautery, PDT, laser, topical
imiquimod and cryosurgery; however, in the majority of
cases these treatments should not be ﬁrst line due to the
risk of recurrence but may be a good option in the elderly
population. In addition, it is important to consider patient
choice, feasibility, side eﬀects, and cosmetic outcome when
planning management.
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